In Brief: JB Williams
This article was originally published in The Tan Sheet
Executive Summary
JB Williams: Submits "belated" comments to FDA regarding the January 1988 tentative final monograph for OTC oral health care products on April 18. The company, which sells Cepacol Maximum Strength Sore Throat Spray, is requesting that the agency "amend the directions for dosage forms" to allow "continued use of directions similar to or the same as those already in use for marketed OTC anesthetic/analgesic sprays." Directions for use in the TFM would instruct consumers to "gargle, swish around or allow to remain in place for at least one minute and then spit out" a liquid anesthetic/analgesic, which the company points out is inappropriate for sprays...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning